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ARTICLE
Epidemiology
Characteristics of The Cancer Genome Atlas cases relative to
U.S. general population cancer cases
Xiaoyan Wang1, Joseph T. Steensma1, Matthew H. Bailey2,3, Qianxi Feng1, Hannah Padda1 and Kimberly J. Johnson1,4
BACKGROUND: Despite anecdotal reports of differences in clinical and demographic characteristics of The Cancer Genome Atlas
(TCGA) relative to general population cancer cases, differences have not been systematically evaluated.
METHODS: Data from 11,160 cases with 33 cancer types were ascertained from TCGA data portal. Corresponding data from the
Surveillance, Epidemiology, and End Results (SEER) 18 and North American Association of Central Cancer Registries databases were
obtained. Differences in characteristics were compared using Student’s t, Chi-square, and Fisher’s exact tests. Differences in mean
survival months were assessed using restricted mean survival time analysis and generalised linear model.
RESULTS: TCGA cases were 3.9 years (95% CI 1.7–6.2) younger on average than SEER cases, with a signiﬁcantly younger mean age
for 20/33 cancer types. Although most cancer types had a similar sex distribution, race and stage at diagnosis distributions were
disproportional for 13/18 and 25/26 assessed cancer types, respectively. Using 12 months as an end point, the observed mean
survival months were longer for 27 of 33 TCGA cancer types.
CONCLUSIONS: Differences exist in the characteristics of TCGA vs. general population cancer cases. Our study highlights
population subgroups where increased sample collection is warranted to increase the applicability of cancer genomic research
results to all individuals.
British Journal of Cancer (2018) 119:885–892; https://doi.org/10.1038/s41416-018-0140-8
INTRODUCTION
In recent years, progress in genome sequencing technologies and
bioinformatics has provided enormous gains in understanding of
the molecular aberrations associated with the development of
various cancers. The emergence of publicly available cancer
genomic datasets, including The Cancer Genome Atlas (TCGA),
facilitates the comprehensive understanding of the molecular
pathogenesis of cancer and is allowing for the development of
new strategies to improve cancer diagnosis, therapy, and
prevention. By analysing these publicly available genomic data,
many novel disease-associated genes have been uncovered.1,2
TCGA was formed in 2005 when the U.S. National Cancer and
National Human Genome Research Institutes teamed together to
support the launch of the project to comprehensively map various
cancer genomic changes. To date, more than 11,000 individuals with
33 cancer types have been included in the cohort.3,4 These data have
thus far contributed to >2000 studies of various cancers in PubMed.
The cohort composition for each cancer type is an important
consideration since the results generated from these cases may be
used to make inferences about the respective cancer type among
the general population. Prior studies have shown that race, which
is often used as a proxy for ancestry and social exposures, is related
to the pathogenesis of cancer and different genetic backgrounds
in common tumour types may inﬂuence clinical outcome and
response to therapy.5–7 Evidence has shown that somatic mutation
frequency differs by race in various cancer types,8–10 implying that
factors associated with race can impact the somatic mutation
landscape. Other evidence also highlights the implications of sex
and age dissimilarities in genetic susceptibility to cancer.11–13 For
these reasons and because TCGA data was assembled mainly from
an eligible convenience sample of cancer patients with strict
sample selection criteria,14 it is important to understand similarities
and differences in the characteristics of individuals who have
contributed samples to TCGA relative to those of the general
population of individuals diagnosed with cancer. A previous study
of TCGA cases found that race/ethnicity disparities exist relative to
the U.S. general population for ten cancer types examined
comprising 5729 cases.15 Another study that analysed nine
different cancer types in TCGA indicated a dissimilar age
distribution in comparison with corresponding cases in the Surveil-
lance, Epidemiology, and End Results (SEER) database.16 However,
differences in demographic and clinical characteristics beyond
race/ethnicity and age between members of the TCGA and the
general U.S. population of cancer cases have not been system-
atically characterised.
In this study, we extend the results from previous studies by
comparing demographic and clinical characteristics (age at
diagnosis, sex, race, stage at diagnosis, and survival months)
between TCGA cases with 33 cancer types and cases in two
population-based databases: (1) the SEER 18 database that
currently covers ~28% of the U.S. population,17 and (2) the U.S.
combined registries of North American Association of Central
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Cancer Registries (NAACCR) that covers cancer registrations in all
50 states and the District of Columbia.18
METHODS
Population
Three separate data sources were used in this study: TCGA,19 the
SEER 18 database,17 and the NAACCR public use dataset.20 Data
from individuals diagnosed with 33 cancer types were extracted
from TCGA. No duplicate cases were found across various cancer
types as determined by matching TCGA case IDs. Individuals with
corresponding cancer types in SEER were identiﬁed using the third
edition of the International Classiﬁcation of Diseases for Oncology
(ICD-O-3) by primary site and histology/behavior (Supplementary
Table 1). To compare TCGA cases to a contemporary population of
individuals diagnosed with cancer, only cases diagnosed with a
primary malignancy from 2010 to 2013 in SEER were included.
Since SEER intentionally oversamples U.S. minority populations,21
we used data from NAACCR to compare race distributions. This
public use dataset published in the annual Cancer in North
American (CiNA) Volumes covers cancer registrations in all
50 states and the District of Columbia, approaching 100%
coverage of the U.S. population in the most recent time period.22
The most current ﬁve years (2009–2013) of data for U.S. and
Canadian individuals diagnosed with cancer were available in this
dataset. In this study, only U.S. cancer cases with available race
data were included. The corresponding cancer types in NAACCR
were deﬁned using the cancer sites as denoted in Supplementary
Table 1.
Variables
XML ﬁles from TCGA containing data on demographics, cancer
variables, and follow-up status were downloaded from the
National Cancer Institute Genomic Data Commons data portal19
on 22 December 2016. Python 3.6.0 was used to parse these
ﬁles and extract the variables. Demographic data including
diagnosis age, sex, and race were extracted from the
“clin_shared:age_at_initial_pathologic_diagnosis”, “shared:gen-
der”, “clin_shared:race” ﬁelds. Race was categorised as White,
Black (African American), and Other (Asian, American Indian, or
Alaska Native). Ethnicity was not included in this analysis due to
the large proportion (24%) of cases with missing data for this ﬁeld.
Clinical information was extracted from the “shared_stage:
clinical_stage”, “shared_stage:pathological_stage”, “shared_last_-
contact_days_to”, and “shared_death_days_to” ﬁelds. Stage was
deﬁned according to American Joint Committee on Cancer (AJCC)
staging that includes categories I, II, III, and IV. Survival months
were calculated using the “shared_last_contact_days_to” ﬁeld for
cases who were still alive and “shared_death_days_to ﬁeld” for
cases who were deceased during the follow-up period divided by
days in a month (365.24/12).23 Similarly, the demographic and
clinical data of the 33 corresponding cancers were extracted from
the SEER 18 database using SEER*Stat 8.3.4. Diagnosis age was
based on the SEER variable “Age at diagnosis”. Race classiﬁcations
were based on the “Race recode (W, B, AI, API)” variable and
deﬁned the same as above. Stage at diagnosis was deﬁned using
the “Derived AJCC Stage Group (7th edition 2010+)” variable.
Survival months were deﬁned using the “Survival months”
variable. In NAACCR, the race categories were based on the “Race
(Includes Hispanic)” variable and deﬁned the same as for TCGA.
Statistical analysis
Stata version 14 was used for all analyses. Student’s t-test and
Cohen’s d, a measure of effect size, were used to identify and
quantify the statistical differences and effect sizes in diagnosis
age. Cohen’s d is calculated as the difference between two means
divided by the pooled standard deviation.24 By convention,
Cohen’s d ≥ 0.3 indicates at least a moderate effect size. Ordinary
least squares regression was used to estimate the overall mean
difference in diagnosis age between TCGA and SEER cases with
adjustment for cancer types. Chi-square and Fisher’s exact tests
were used to identify proportion differences in sex, race, and
stage. Additionally, for race and stage comparisons, adjusted
residuals were used to determine categories with the largest
difference relative to sample size. An adjusted residual ≥ 2.0
indicates that there was a signiﬁcantly greater proportion of a
particular race or stage category among TCGA cases than in the
comparison population (i.e., NAACCR or SEER), while an adjusted
residual ≤ −2.0 indicates a signiﬁcantly lower proportion. We also
quantiﬁed the mean all-cause survival months using restricted
mean survival time (RMST) analysis25 using 12 months as the end
point to ensure that all TCGA cases that were included have the
same window of observation. Since all TCGA cases were
diagnosed prior to 2014, all had at least 12 months of follow-up
time except for the cases who died during this period. For cases
with over 12 survival months, the survival months were truncated
at 12. The RMST approach is valid for any distribution of time to
event.25–29 The between-group difference in mean survival with
corresponding 95% conﬁdence intervals (CIs) was estimated at 12-
month horizon with adjustment for diagnosis age, sex, race, and
stage if available for a speciﬁc cancer type, and a subsequent
generalised linear model with robust standard errors. Statistical
tests for all analyses were two-tailed tests and the critical value for
alpha for all tests was 0.05.
RESULTS
Of 11,160 TCGA cases with 33 cancer types diagnosed between
1978 and 2013, 1097 cases were diagnosed with breast invasive
carcinoma (BRCA) followed by glioblastoma multiforme (GBM, n=
596), ovarian serous cystadenocarcinoma (OV, n= 587), uterine
corpus endometrial carcinoma (UCEC, n= 548), kidney renal clear
cell carcinoma (KIRC, n= 537), head and neck squamous cell
carcinoma (HNSC, n= 528), lung adenocarcinoma (LUAD, n=
522), and brain lower grade glioma (LGG, n= 515). Six cancers
including adrenocortical carcinoma (ACC), cholangiocarcinoma
(CHOL), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC),
mesothelioma (MESO), uterine carcinosarcoma (UCS), and uveal
melanoma (UVM) had < 100 cases each. Among the correspond-
ing 33 diagnoses in SEER, the number of cases ranged from 164
(UCS) to 203,828 (BRCA). In NAACCR, the number of cases ranged
from 15,705 (MESO) to 1,085,443 (BRCA). Demographic and clinical
characteristics of TCGA and SEER cases are shown in Table 1. The
race distribution of TCGA and NAACCR cases is shown in Table 2.
Age at diagnosis
Overall, the mean diagnosis age of TCGA cases was 3.9 years
younger (95% CI: 1.7–6.2, P < 0.001) than SEER cases after
adjusting for cancer types (data not shown). The mean diagnosis
age of TCGA cancer cases was not signiﬁcantly different from that
of SEER cases for a minority of cancers (CHOL, colon adenocarci-
noma (COAD), KIRC, kidney renal papillary cell carcinoma (KIRP),
pheochromocytoma and paraganglioma (PCPG), sarcoma (SARC),
stomach adenocarcinoma (STAD), thymoma (THYM), and UVM). In
contrast, for most cancer types (24/33), there were statistically
signiﬁcant differences in the mean diagnosis age. Among these,
the majority (20/24) had a signiﬁcantly younger mean diagnosis
age with the exceptions of LGG, rectum adenocarcinoma (READ),
UCEC, and UCS, TCGA cases that had statistically signiﬁcant older
mean diagnosis age than SEER cases (Fig. 1). The difference in the
mean diagnosis age was especially pronounced for DLBC (8.4 ± 2.4
years younger in TCGA), oesophageal carcinoma (ESCA, 3.8 ± 0.9
years younger), kidney chromophobe (KICH, 7.4 ± 1.3 years
younger), LGG (7.5 ± 0.9 years older), liver hepatocellular carci-
noma (LIHC, 3.6 ± 0.7 years younger), MESO (8.4 ± 1.3 years
younger), prostate adenocarcinoma (PRAD, 4.7 ± 0.4 years
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younger), and UCS (4.3 ± 1.5 years older) cases where the absolute
effect size for the diagnosis age difference (Cohen’s d) was ≥ 0.3
(Table 3).
Sex
For most cancer types (22/27), the observed sex distribution for
TCGA cases was similar to SEER cases. Lung squamous cell
carcinoma (LUSC), skin cutaneous melanoma (SKCM), and thyroid
carcinoma (THCA) had a signiﬁcantly higher proportion of male
cases (74.0% vs. 62.4%, 61.7% vs. 56.6%, and 26.8% vs. 22.8%,
respectively), while LIHC and SARC cases had an excess of female
cases (32.4% vs. 22.6%, 54.4% vs. 46.7%) in TCGA vs. SEER (Tables 1
and 3).
Race
Overall, compared to the NAACCR cases, individuals whose
reported race was Other (Asian, American Indian, or Alaska Native)
were over-represented in TCGA. The observed race distribution
Table 2. Race distribution of TCGA and NAACCR cases
Cancer types Total White Black Other
TCGA N NAACCR N TCGA N (%) NAACCR N (%) TCGA N (%) NAACCR N (%) TCGA N (%) NAACCR N (%)
All cancers 5899 4,834,006 4845 (82.1) 4,118,891 (85.2) 500 (8.5) 548,447 (11.3) 554 (9.4) 166,668 (3.4)
BLCA 394 335,620 327 (83.0) 310,352 (92.5) 23 (5.8) 18,912 (5.6) 44 (11.2) 6356 (1.9)
BRCA 1002 1,085,443 758 (75.7) 913,884 (84.2) 183 (18.3) 128,208 (11.8) 61 (6.1) 43,351 (4.0)
CESC 271 59,092 221 (81.6) 46,030 (77.9) 30 (11.1) 9902 (16.8) 20 (7.4) 3160 (5.4)
COAD 285 477,271 215 (75.4) 397,760 (83.3) 59 (50.6) 62,360 (13.1) 11 (3.9) 17,151 (3.6)
ESCA 165 78,445 114 (69.1) 68,590 (87.4) 5 (3.0) 8034 (10.2) 46 (27.9) 1821 (2.3)
HNSC 513 416,929 454 (88.5) 364,624 (87.5) 48 (9.4) 40,315 (9.7) 11 (2.1) 11,990 (2.9)
LAML 198 65,266 181 (91.4) 56,612 (86.7) 15 (7.6) 5983 (9.2) 2 (1.0) 2671 (4.1)
LIHC 367 131,074 189 (51.5) 100,398 (76.6) 17 (4.6) 19,865 (15.2) 161 (43.9) 10,811 (8.3)
MESO 87 15,705 85 (97.7) 14,745 (93.9) 1 (1.2) 740 (4.7) 1 (1.2) 220 (1.4)
OV 556 102,308 502 (90.3) 88,406 (86.4) 34 (6.1) 9521 (9.3) 20 (3.6) 4381 (4.3)
PAAD 180 205,375 162 (90.0) 172,558 (84.0) 7 (3.9) 25,856 (12.6) 11 (6.1) 6961 (3.4)
PRAD 156 944,300 147 (94.2) 768,438 (81.4) 7 (4.5) 153,082 (16.2) 2 (1.3) 22,780 (2.4)
READ 89 188,774 82 (92.1) 157,903 (83.7) 6 (6.7) 21,534 (11.4) 1 (1.1) 9337 (5.0)
SARC 252 51,566 228 (90.5) 43,208 (83.8) 18 (7.1) 6336 (12.3) 6 (2.4) 2022 (3.9)
SKCM 460 314,232 447 (97.2) 311,095 (99.0) 1 (0.2) 1747 (0.6) 12 (2.6) 1390 (0.4)
STAD 381 108,778 279 (73.2) 83,030 (76.3) 13 (3.4) 17,535 (16.1) 89 (23.4) 8213 (7.6)
TGCT 129 38,765 119 (92.3) 36,311 (93.7) 6 (4.7) 1380 (3.6) 4 (3.1) 1074 (2.8)
THCA 414 215,063 335 (80.9) 184,947 (86.0) 27 (6.5) 17,137 (8.0) 52 (12.6) 12,979 (6.0)
BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD colon
adenocarcinoma, ESCA oesophageal carcinoma, HNSC head and neck squamous cell carcinoma, LAML acute myeloid leukaemia, LIHC liver hepatocellular
carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PRAD prostate adenocarcinoma, READ rectum
adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma, STAD stomach adenocarcinoma, TGCT testicular germ cell tumours, THCA thyroid carcinoma.





































































Fig. 1 Age at diagnosis difference between TCGA and SEER cases. Filled diamonds indicate a statistically signiﬁcant difference (P < 0.05). The y-
axis shows the effect size in terms of Cohen’s d. Cohen’s d was calculated as the difference between the mean diagnosis age for TCGA and
SEER cases divided by the pooled standard deviation24 of each cancer with Cohen’s d > |±0.3| indicating at least a moderate effect size.
Cohen’s d < 0 indicates TCGA cases with a younger mean age than SEER cases
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was disproportional for 13/18 cancer types (Fig. 2a). Among the 13
cancers, eight (bladder urothelial carcinoma (BLCA), BRCA, ESCA,
LIHC, pancreatic adenocarcinoma (PAAD), SKCM, STAD, and THCA)
had a signiﬁcantly higher percentage (adjusted residuals ≥ 2) of
individuals with reported Other race (Asian, American Indian, or
Alaska Native) and eight (cervical squamous cell carcinoma and
endocervical adenocarcinoma (CESC), ESCA, LIHC, OV, PAAD,
PRAD, SARC, and STAD) had a lower percentage (adjusted
residuals ≤ −2) of reported Black race in TCGA vs. NAACCR
(Table 3).
Stage at diagnosis
For the 26 TCGA cancer types with stage information, evidence for
stage dissimilarities was observed for most cancer types (25/26)
(Fig. 2b). Speciﬁcally, compared to SEER cases, 16 cancers had a
signiﬁcantly lower proportion of stage I in the TCGA cohort, 19
Table 3. Differences of demographic and clinical characteristics distribution among TCGA, SEER, and NAACCR casesa
Cancer
types
Age Sex Race Stage Survival months
Cohen’s d Pb Pc Whited Blackd Otherd Pc Id IId IIId IVd Pc Difference in mean
survival (95% CI)
ACC −0.27 0.009 0.63 — — — — 2.04 3.27 1.6 −5.24 <0.001 1.46 (0.87, 2.06)e
BLCA −0.17 <0.001 0.25 −7.12 0.17 13.46 <0.001 −20.63 2.85 19.13 10.57 <0.001 1.54 (1.29, 1.80)e
BRCA −0.17 <0.001 0.15 −7.41 6.32 3.38 <0.001 −21.17 17.27 11.54 −5.48 <0.001 0.11 (0.08, 0.15)e
CESC −0.12 0.04 — 1.5 −2.45 1.48 0.02 1.84 4.76 −2.99 −3.74 <0.001 0.11 (-0.07, 0.30)f
CHOL −0.28 0.07 0.47 — — — — 4.65 1.37 0.13 −4.71 <0.001 2.35 (1.32, 3.39)e
COAD 0.02 0.73 0.13 −3.58 3.82 0.24 0.001 −3.11 5.79 0.83 −3.95 <0.001 0.73 (0.51, 0.96)e
DLBC −0.5 <0.001 0.21 — — — — 0.3 2.67 −1.4 −1.38 0.04 1.37 (0.95, 1.78)e
ESCA −0.33 <0.001 0.06 −7.09 −3.05 21.54 <0.001 −2.35 10.24 1.94 −8.13 <0.001 0.89 (0.44, 1.35)e
GBM −0.29 <0.001 0.05 — — — — — — — — — 0.90 (0.58, 1.22)g
HNSC −0.13 0.003 0.17 0.71 −0.24 −0.99 0.59 −8.37 2.82 0.57 4.69 <0.001 0.42 (0.19, 0.64)e
KICH −0.53 <0.001 0.96 — — — — −3.85 3.01 0.71 2.78 <0.001 0.07 (−0.17, 0.31)e
KIRC 0.02 0.57 0.24 — — — — −5.82 1.58 3.91 2.79 <0.001 0.09 (−0.10, 0.27)e
KIRP 0.01 0.84 0.74 — — — — −2.62 −1.13 4.98 −0.19 <0.001 0.36 (0.24, 0.49)e
LAML −0.24 <0.001 0.95 1.94 −0.77 −2.19 0.06 — — — — — 1.86 (1.34, 2.39)g
LGG 0.41 <0.001 0.72 — — — — — — — — — 0.52 (0.30, 0.74)g
LIHC −0.33 <0.001 <0.001 −11.33 −5.61 24.64 <0.001 3.5 2.15 2.71 −9 <0.001 1.77 (1.43, 2.11)e
LUAD −0.18 <0.001 0.6 — — — — 16.86 14.17 0.47 −22.11 <0.001 0.48 (0.28, 0.69)e
LUSC −0.24 <0.001 <0.001 — — — — 15.67 13.07 −6.1 −16.56 <0.001 0.66 (0.37, 0.95)e
MESO −0.69 <0.001 0.18 1.48 −1.57 −0.2 0.29 −2.27 2.15 6.09 −4.77 <0.001 1.60 (0.86, 2.34)e
OV −0.24 <0.001 — 2.67 −2.59 −0.8 0.02 −6.61 −2.31 11.37 −7.13 <0.001 0.09 (−0.14, 0.31)f
PAAD −0.19 0.01 0.33 2.19 −3.52 2.02 <0.001 1.06 16.22 −3.41 −13.34 <0.001 1.13 (0.66, 1.61)e
PCPG −0.17 0.12 0.13 — — — — — — — — — 0.54 (0.14, 0.95)g
PRAD −0.52 <0.001 — 4.12 −3.97 0.92 <0.001 — — — — — 0.05 (0.03, 0.07)h
READ 0.22 0.002 0.25 2.17 −1.39 −1.67 0.08 −3.3 3.33 1.15 −0.85 0.001 0.76 (0.56, 0.95)e
SARC 0.08 0.12 0.02 2.88 −2.48 −1.26 0.02 — — — — — 2.47 (2.19, 2.74)g
SKCM −0.1 0.03 0.03 −3.69 −1.04 6.68 <0.001 −26.25 12.85 24.84 1.6 <0.001 0.37 (0.24, 0.51)e
STAD −0.04 0.31 0.2 −1.42 −6.74 11.62 <0.001 −3.91 8.59 10.49 −12.13 <0.001 0.89 (0.62, 1.15)e
TGCT −0.21 0.003 — 0.66 0.67 0.23 0.78 1.84 −1.4 −0.99 — 0.18 0.0003 (−0.18, 0.18)f
THCA −0.12 0.008 0.03 −2.97 −1.09 5.57 <0.001 −7.78 2.44 6.51 2.54 <0.001 0.15 (0.09, 0.21)e
THYM −0.01 0.95 0.25 — — — — — — — — — 0.35 (0.14, 0.57)g
UCEC 0.21 <0.001 — — — — — −9.27 5.24 8.86 −0.32 <0.001 0.29 (0.18, 0.40)f
UCS 0.4 0.005 — — — — — 4.04 0.35 0.52 −4 <0.001 1.04 (0.04, 2.04)f
UVM 0.1 0.4 0.44 — — — — −6.15 −0.1 7.08 1.45 <0.001 −0.01 (−0.40, 0.37)e
ACC adrenocortical carcinoma, BLCA bladder urothelial carcinoma, BRCA breast invasive carcinoma, CESC cervical squamous cell carcinoma and endocervical
adenocarcinoma, CHOL cholangiocarcinoma, COAD colon adenocarcinoma, DLBC lymphoid neoplasm diffuse large B-cell lymphoma, ESCA oesophageal
carcinoma, GBM glioblastoma multiforme, HNSC head and neck squamous cell carcinoma, KICH kidney chromophobe, KIRC kidney renal clear cell carcinoma,
KIRP kidney renal papillary cell carcinoma, LAML acute myeloid leukaemia, LGG brain lower grade glioma, LIHC liver hepatocellular carcinoma, LUAD lung
adenocarcinoma, LUSC lung squamous cell carcinoma, MESO mesothelioma, OV ovarian serous cystadenocarcinoma, PAAD pancreatic adenocarcinoma, PCPG
pheochromocytoma and paraganglioma, PRAD prostate adenocarcinoma, READ rectum adenocarcinoma, SARC sarcoma, SKCM skin cutaneous melanoma,
STAD stomach adenocarcinoma, TGCT testicular germ cell tumours, THCA thyroid carcinoma, THYM thymoma, UCEC uterine corpus endometrial carcinoma, UCS
uterine carcinosarcoma, UVM uveal melanoma. aP-values < 0.05, its corresponding effect size and 95% conﬁdence intervals, and adjusted residuals that exceed
|± 2| are bolded. bP-value was calculated using Student’s t-test. cP-value of comparisons between TCGA and SEER (sex, stage at diagnosis) or NAACCR (race)
cases was using the Chi-square test. For CHOL, KICH, UCS, and UVM, Fisher’s exact test was used for the comparison of stage at diagnosis. dAdjusted residuals.
eGeneralised linear models adjusted for age at diagnosis, sex, race, and stage at diagnosis. fGeneralised linear models adjusted for age at diagnosis, race, and
stage at diagnosis. gGeneralised linear models adjusted for age at diagnosis, sex, and race. hGeneralised linear models adjusted for age at diagnosis and race
Characteristics of The Cancer Genome Atlas...













































































































































































Stage I Stage II










Fig. 2 Race and stage proportion difference. a Race proportion of TCGA and NAACCR cases. b Stage proportion of TCGA and SEER cases. The








































































Fig. 3 Survival months difference between TCGA and SEER cases. Mean survival months difference at 12-months of follow-up with
corresponding 95% CIs. Dots indicate the mean survival months difference and lines represent its 95% CIs. The y-axis below zero
indicates TCGA cases with a shorter survival time than SEER cases
Characteristics of The Cancer Genome Atlas...
X Wang et al.
890
cancers had a signiﬁcantly higher proportion of stage II, 12 cancers
had a signiﬁcantly higher proportion of stage III, and 14 cancers
had a signiﬁcantly lower proportion of stage IV (Table 3).
Survival months
Using 12 months as an end point, the adjusted mean all-cause
survival months were signiﬁcantly longer for cases with 27/33
cancer types in TCGA relative to SEER. For the remaining six
cancer types (CESC, KICH, KIRC, OV, testicular germ cell tumours
(TGCT), and UVM), no statistically signiﬁcant difference was found
(Fig. 3). It is noteworthy that for CHOL and SARC, TCGA cases
lived an average of over 2 months (2.35 and 2.47 months,
respectively) longer than SEER cases after 12 months of follow-up
(Table 3).
DISCUSSION
In this study, we observed that despite an approximately equal sex
distribution for most cancer types included in TCGA vs. SEER data,
differences exist in mean diagnosis age, race, stage at diagnosis
distributions, and mean survival months. Generally, our analysis
indicates that TCGA cases are younger and survive longer than
those from SEER.
A previous study comparing the characteristics of TCGA cases to
the U.S. general population was conducted by Spratt et al.15 The
authors reported that TCGA cases with 10 cancer types compared
to the U.S. population were 77% vs. 64% White, 12% vs. 12% Black,
3% vs. 5% Asian, 3% vs. 16% Hispanic, and 0.5% vs. 1–2% Native
Hawaiian, Paciﬁc Islander, Alaskan Native, or American Indian
descent. White cases were over-represented and Asian and
Hispanic cases were under-represented compared to the general
population. However, the Spratt et al. study used the general U.S.
population as the comparator, which is different from the
composition of U.S. cancer patients who are one of the prime
beneﬁciaries of TCGA results.
Another more recent study compared the distribution of TCGA
cases by age to SEER cases for nine cancer types.16 Similar to our
study, the age distributions for cases in the SEER database were
skewed older than those in the TCGA data for nearly all cancer
types examined. Speciﬁcally, TCGA cases < 70 years were well
represented across most tumour types, but cases aged 80–99
years were under-represented for all cancers. These data are also
consistent with that from clinical trials.30 TCGA specimens are
primarily from U.S. academic institutions,3,15 suggesting that
younger patients are more likely to be seen at academic centres
and participate in research where the samples were acquired. A
systematic review on the recruitment of older cancer patients to
clinical trials reported that age is a signiﬁcant barrier to
recruitment.31 For example, Kemeny et al. found that 68% of
younger stage II breast cancer patients were offered a trial
vs. 34% of the older patients (P < 0.001).32 It is presumed that older
patients may need extra time and resources to access available
clinical trials or they are often excluded because they do not meet
eligibility criteria.31 Our results emphasize the importance of
increasing access of older cancer patients to cancer genomic
projects to increase the applicability of the ﬁndings to these
patients.
Racial disparities in cancer incidence and survival have been
well documented among various cancers. Although socioeco-
nomic and cultural differences that differ between racial groups
can explain some of the disparities, recent progress in cancer
genomic sequencing allows for a molecular understanding.33,34
Genomic landscape differences that co-vary by race, a marker of
ancestry, may inﬂuence cancer treatment. For example, one study
reported that even after adjusting for smoking status and sex, race
was still signiﬁcantly associated with EGFR mutations.35 EGFR
mutations were highly prevalent in Asians at 30% vs. 7% in
Whites.36 In addition, results from a meta-analysis of randomised
controlled trials have reported that compared with Caucasians,
Asians have a higher survival and response rate to chemother-
apy.37 In our study, the race distribution was notably dissimilar for
13/18 cancers, with 8/13 cancers having under-representation in
individuals with Black race, which may translate to a distinct
genomic landscape that may be under-represented for many
cancer types. Notably, 8 of these 13 cancers had higher
representation by individuals with Other race (Asian, American
Indian, or Alaska Native). This over-representation may be due to
TCGA cancers with small sample sizes where a relatively large
proportion can be found even only with few cases in the
Other population.
Stage is a well-established predictor of cancer prognosis and
survival.38 Studies have also reported notable genetic variation in
cancers by stage.39,40 In our study, stage dissimilarities existed for
almost all cancer types (25/26). However, these identiﬁed
differences between datasets may be due to the fact that only
individuals who had a resection procedure were included in
TCGA.14 Individuals with unresectable cancers, such as cancers
with advanced stage or metastatic cancer,41 did not meet the
inclusion criteria of the program, which likely led to a lower stage
distribution of the cases in TCGA compared to SEER. In addition,
other differences may have contributed to stage differences
including the sample eligibility requirements of only untreated
ﬁrst primary tumour samples being fresh frozen.14
To our knowledge, this is the largest study to compare clinical
characteristics of TCGA cancer cases to a sample of the general
population of U.S. cancer cases. However, our study has
limitations. No speciﬁc diagnosis criteria for each cancer type
have been published for TCGA to our knowledge. Thus, the
corresponding cancers in SEER were matched by cancer site and
histology, and identiﬁed by ICD-O-3 primary site and
histology/behavior code. Moreover, cases with certain cancers
had missing race, stage, and survival months information.
Particularly, 6/33 TCGA cancer types (THCA, LUSC, PRAD, COAD,
READ, and UVM) had over 15% missing data on race, and 5/26
SEER cancers (BLCA, LIHC, MESO, CHOL, and UVM) had over 15%
missing data on stage. In addition, for the race comparison, only
18 cancers in NAACCR were identiﬁed with sites matching to
those of TCGA cases.
In conclusion, we found dissimilarities in the distributions of
demographic and clinical characteristics between TCGA and
general population cancer cases for the majority of cancers.
Increased awareness of under-represented groups by researchers
conducting cancer genomic research will allow for targeted efforts
that increase the representativeness of genomic data that is
important for precision medicine.
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